Dermatology & Plastic Surgery Institute Outcomes
Surgical Quality Improvement
Dermatology & Plastic Surgery Institute Outcomes
Dermatology & Plastic Surgery Institute Surgery ACS NSQIP Outcomes
January 1, 2024 – December 31, 2024
The American College of Surgeons National Surgical Quality Improvement Program (ACS NSQIP®) objectively measures and reports risk-adjusted surgical outcomes based on a defined sampling and abstraction methodology. These outcomes data reflect Cleveland Clinic’s Dermatology & Plastic Surgery Institute surgery ACS NSQIP performance benchmarked against 468 participating sites.
| Dermatology & Plastic Surgery (468 Sites) | N | Observed | Expected |
|---|---|---|---|
| 30 Day Morbidity | 438 | 8.22% | 6.59% |
| Cardiac | 438 | 0.46% | 0.20% |
| Pneumonia | 438 | 0.00% | 0.05% |
| Deep Vein Thrombosis (DVT) / Pulmonary Embolus | 438 | 0.91% | 0.45% |
| Renal Failure | 438 | 0.00% | 0.04% |
| Urinary Tract Infection (UTI) | 438 | 0.46% | 0.27% |
| Surgical Site Infection (SSI) | 438 | 6.62% | 5.16% |
| Sepsis | 438 | 0.00% | 0.22% |
| Unplanned Reoperation | 438 | 7.99% | 6.22% |
| Unplanned Readmissionᵃ | 438 | 6.16% | 3.63% |
American College of Surgeons National Surgical Quality Improvement Program, 2025.
ACS NSQIP® Semiannual Report July, 2025, Chicago: American College of Surgeons.
ᵃIdentified as a statistical outlier (higher than expected) by the ACS NSQIP hierarchical model.
